搜索
Collegium Pharmaceutical Inc
COLL添加自选
33.780USD
-1.050-3.01%
收盘 05/15, 16:00（美东）报价延迟15分钟
1.10B总市值
14.32市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.01%
5天
-10.63%
1月
+2.24%
6月
-26.53%
今年开始到现在
-27.04%
1年
+11.74%
TradingKey Collegium Pharmaceutical Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Collegium Pharmaceutical Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名12/155位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价54.33。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Collegium Pharmaceutical Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Collegium Pharmaceutical Inc亮点
亮点风险
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
业绩高增长
公司营业收入稳步增长，连续3年增长37.72%
利润高增长
公司净利润处于行业前列，最新年度总收入780.57M美元
估值合理
公司最新PE估值14.32，处于3年历史合理位
机构减仓
最新机构持股38.69M股，环比减少9.82%
保罗·都铎·琼斯持仓
明星投资者保罗·都铎·琼斯持仓，最新持仓市值17.18K
分析师目标
根据
6
位分析师
买入
评级
54.333
目标均价
+56.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Collegium Pharmaceutical Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Collegium Pharmaceutical Inc简介
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
公司代码COLL
公司Collegium Pharmaceutical Inc
CEOKarnani (Vikram)
网址https://www.collegiumpharma.com/
相关品种
